Examkin

Question

Difficulty: Very hardGenetic and Molecular Mechanisms

A 4-month-old male infant is evaluated in the pediatric neurology clinic for severe generalized hypotonia, a weak cry, and absent deep tendon reflexes. Physical examination reveals prominent tongue fasciculations and paradoxical breathing. Genetic testing confirms a homozygous deletion of the survival motor neuron 1 (SMN1) gene. The medical team recommends initiating therapy with an intrathecal antisense oligonucleotide (ASO) designed to modulate the expression of the paralogous SMN2 gene. Arrange the following molecular and cellular events in the exact chronological order by which this targeted genetic therapy exerts its clinical effect, from initial molecular binding to ultimate cellular rescue.

  1. 1The antisense oligonucleotide binds to the intronic splicing silencer N1 (ISS-N1) sequence located in intron 7 of the SMN2 pre-mRNA.
  2. 2Steric hindrance prevents the binding of the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) splicing repressor.
  3. 3The spliceosome recognizes adjacent splice sites, leading to the incorporation of exon 7 into the mature mRNA transcript.
  4. 4Ribosomes translate the correctly spliced mature mRNA into a full-length, structurally stable survival motor neuron (SMN) protein.
  5. 5The functional SMN protein complex facilitates small nuclear ribonucleoprotein (snRNP) assembly, rescuing motor neuron viability.

Answer

The correct sequence begins with the targeted binding of the ASO to the SMN2 pre-mRNA, followed by the steric displacement of splicing repressors, successful inclusion of exon 7 by the spliceosome, translation of a stable full-length SMN protein, and ultimately the restoration of cellular snRNP biogenesis.
The precise molecular mechanism of nusinersen (an ASO for Spinal Muscular Atrophy) requires chronological understanding of molecular genetics. First, the ASO binds to the intronic splicing silencer N1 (ISS-N1) in the SMN2 pre-mRNA. Second, this binding sterically blocks the attachment of the splicing repressor hnRNP A1. Third, in the absence of the repressor, the spliceosome successfully recognizes the splice sites and includes exon 7. Fourth, this mature mRNA is translated into a full-length, stable SMN protein. Finally, the restored SMN protein complex resumes its critical cellular function in assembling small nuclear ribonucleoproteins (snRNPs), thereby preventing motor neuron apoptosis.

Step-by-Step Solution

1
Identify the genetic target of the therapeutic intervention.
The therapy is an antisense oligonucleotide targeting the SMN2 gene's pre-mRNA.
Understanding the drug class determines that its action occurs post-transcriptionally at the RNA level.
2
Determine the exact binding site and immediate molecular consequence.
The ASO binds to the ISS-N1 region in intron 7, which sterically hinders the binding of the splicing repressor hnRNP A1.
This specific structural interference is the primary mechanism of action for altering the splicing cascade.
3
Trace the downstream effect of repressor displacement on the splicing machinery.
The displacement of hnRNP A1 allows the spliceosome to recognize and include exon 7 in the mature mRNA transcript.
Exon 7 inclusion corrects the inherent splicing defect characteristic of the paralogous SMN2 gene.
4
Follow the mature mRNA to its functional protein product and cellular outcome.
The full-length mRNA is translated into a stable SMN protein, which then fulfills its vital role in snRNP biogenesis, ensuring motor neuron survival.
This links the initial molecular correction to the ultimate cellular and phenotypic rescue.

Key Concept

The pharmacogenomic mechanism of antisense oligonucleotide therapy in Spinal Muscular Atrophy involves modulating pre-mRNA splicing of the SMN2 gene to restore full-length SMN protein production.
Rate this question

Topics

Genetic and Molecular Mechanisms

More questions from this topic